Amgen Inc (AMGN) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla f...
Amgen Inc (AMGN) currently trades at a P/E ratio of 30.24 (historical range: 21.83–48.06, median: 28.34), placing it at the 57th percentile — near its historical average, P/S ratio of 6.34 (range: 4.16–6.51, 99th percentile — expensive relative to its history), EV/EBITDA of 103.41 (range: 23.65–233.29, 82th percentile).
Over the historical period (2024-08-30 to 2026-08-28), Amgen Inc's P/E ratio has contracted by 26% over the observed period (from an average of 35.8 to 26.6).
Amgen Inc appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 30.24 | 21.83 | 28.34 | 48.06 | 57th | near its historical average |
| P/S Ratio | 6.34 | 4.16 | 4.94 | 6.51 | 99th | expensive relative to its history |
| EV/EBITDA | 103.41 | 23.65 | 50.45 | 233.29 | 82th | expensive relative to its history |
| FCF Yield | 0.01 | 0.00 | 0.02 | 0.07 | 9th | expensive relative to its history |